Key Points
- U.S. District Judge Amir H. Ali denied the government's motion to dismiss Niagen Bioscience's Administrative Procedure Act suit challenging the FDA's classification of NMN as a dietary supplement.
- Because the government raised a factual challenge to standing, the court considered evidence outside the complaint and found that Niagen had shown competitive injury from the FDA's decision.
- The court found that at least some of Niagen's lost sales occurred before the February 2026 complaint, the point at which standing is measured.
- The court held that Niagen, as a dietary-supplement maker regulated by the statutory definition, falls within the statute's zone of interests.
- The ruling addresses only standing and does not decide whether the FDA's interpretation of the statute is lawful.
A federal judge in the District of Columbia on Nov. 19 refused to dismiss Niagen Bioscience Inc.'s lawsuit against the Food and Drug Administration over the agency's decision to treat nicotinamide mononucleotide, or NMN, as a dietary supplement rather than a drug. The judge ruled that Niagen may sue because the decision let competitors into its market and cost it sales. Under the doctrine of competitor standing, the judge wrote, quoting a 2010 D.C. Circuit decision, "economic actors suffer an injury in fact when agencies lift regulatory restrictions on their competitors or otherwise allow increased competition against them."
U.S. District Judge Amir H. Ali of the U.S. District Court for the District of Columbia denied the government's motion in a 12-page memorandum opinion and order. The government had argued that Niagen lacked both Article III and prudential standing.
The ruling allows Niagen's claims under the Administrative Procedure Act to go forward. Those claims allege that the FDA acted contrary to law, and arbitrarily and capriciously, in classifying NMN. Ali decided only whether Niagen may bring the suit; he did not decide whether the agency read the statute correctly.
The opinion explains why the classification matters. A company marketing a drug faces a strict and often long approval process, usually involving clinical trials. A company marketing a dietary supplement generally files a "new dietary ingredient notification" explaining why the product can "reasonably be expected to be safe," and may sell it after waiting 75 days.
Niagen relies on a provision of the Dietary Supplement Health and Education Act of 1994 that excludes from the supplement category an ingredient under investigation as a new drug, unless it was earlier "marketed as a dietary supplement or as a food." Niagen contends that this earlier marketing had to follow the notification process, which it says never happened for NMN. According to the complaint, the FDA says NMN was already marketed as a supplement. The complaint also alleges that the agency reversed a longstanding contrary position in September 2025.
As the opinion describes them, Niagen's products contain nicotinamide riboside, a building block for NAD+, a compound that "plays a role in cellular function and has potential anti-aging and cognitive benefits." NMN is another such building block. Under the FDA's new interpretation, the opinion says, Niagen's competitors can now introduce NAD+ products based on NMN.
The government disputed the facts behind Niagen's claimed financial injury. Ali therefore agreed with the government that he could look past the complaint to outside evidence. "But the court concludes Niagen has shown competitive injury on this record," he wrote.
That record included a declaration from Niagen's chief financial officer. According to the declaration, Niagen's year-over-year net sales growth was about 36% in the three quarters before the FDA's decision. Growth fell to 16% in the fourth quarter of 2025 and 3% in the first quarter of 2026. Competitors' NMN sales over roughly seven months after the reversal exceeded $14 million, the CFO said. Niagen estimates that it lost at least $15 million in revenue. Its stock closed at $9.90 before the decision, fell to $7.89 the next day and was at $6.93 by the end of the week.
"The court finds that this evidence credibly shows the FDA's decision contributed, at least in part, to a change in Niagen's financial fortunes, causing it injury," Ali wrote. He said in a footnote that the stock decline was not itself the injury but "simply one piece of evidence, among many others," linking the decision to the slowdown in sales.
Ali also relied on the Supreme Court's statement in Diamond Alternative Energy v. EPA that "commonsense economic principles" can be useful in judging standing. "When new competitors enter a market, the existing market players will predictably find themselves facing sales headwinds in most cases," he wrote.
The government asked Ali to discount Niagen's evidence, pointing to upbeat remarks by the company's chief executive. In an October 2025 press release, the CEO said the reversal "could serve to increase awareness of the NAD+ precursor market overall." On a November 2025 earnings call, he said "we haven't noticed anything yet." Ali found that those statements, "while perhaps reflecting a slow appreciation of or undue optimism about the impact of the FDA's reversal on the company's top line, do not show that financial harm did not, in fact, occur."
The government also pointed to what its brief called Niagen's "impressive sales growth" after the decision. Ali answered that growth had "turned sluggish," and that positive growth "does not mean the company experienced no lost sales." He acknowledged the government's point that Niagen had not said precisely when its losses began. Standing is measured when a suit is filed, and Niagen filed in February 2026. Ali found that "at least a small amount of Niagen's lost sales occurred prior to the time of filing."
On prudential standing, Ali applied the zone-of-interests test, which asks whether a plaintiff's interests are arguably among those the statute protects or regulates. The Supreme Court has called that test "not especially demanding." Ali held that Niagen, as a dietary-supplement maker, is directly regulated by the statutory definition at issue.
The government argued that only a company engaged in drug development falls within the relevant zone of interests. "That's too myopic," Ali wrote. He said Niagen's suit to enforce the line between drugs and supplements "coincides with consumers' interest in product safety." Drug makers and supplement makers, he wrote, "both have an interest in proper classification."
The order concludes: "For these reasons, the government's motion to dismiss, ECF No. 20, is denied." The case is Niagen Bioscience Inc. v. U.S. Food and Drug Administration et al., Civil Action No. 26-00309, in the U.S. District Court for the District of Columbia.